Piper Sandler Maintains Overweight on Sensei Biotherapeutics, Lowers Price Target to $10
Piper Sandler analyst Joseph Catanzaro maintains Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight and lowers the price target from $12 to $10.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
3 Penny Stocks Insiders Are Buying: ReWalk Robotics, Evolving Systems And More
Germany’s economy contracted 0.7% on quarter during the last three months of 2021, compared to analysts’ views of a 0.3% drop, sending the German DAX index lower by more than 2% on Friday. Investors, meanwhile, focused on some notable insider trades.
63 Biggest Movers From Yesterday
Gainers
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
Sensei Biotherapeutics Q3 EPS $(0.32) Up From $(3.00) YoY
Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(0.32) per share. This is a 89.33 percent increase over losses of $(3.00) per share from the same period last year.
22 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for NASH and obesity met its primary endpoint. The company also released Q2 results.